Shots:

• Sol-Gel Technologies has entered into an asset purchase agreement with Shenzhen Beimei Pharmaceutical to commercialize Twyneo for treating acne vulgaris across mainland China, Hong Kong, Macau, Taiwan & Israel
• As per the agreement, Beimei gains exclusive commercialization rights to Twyneo across those regions. Sol-Gel is entitled to receive an aggregate of $10M which includes upfront and milestones plus up to $5M net-sales-based royalty
• The company also anticipates future collaborations for the commercialization of both Twyneo and Epsolay across other regions

Ref: Sol-Gel Technologies | Image: Sol-Gel Technologies

Related News:- Sol-Gel Technologies' Twyneo (tretinoin/benzoyl peroxide) Cream Receives the US FDA's Approval for the Treatment of Acne Vulgaris

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com